BioCentury | Jul 29, 2020
Finance

With €27M at launch, Vico revives Prosensa oligonucleotide programs, aims to edit RNA for Rett

...Pureos, and the Droia fund. Mandel-Brehm is an entrepreneur partner at Polaris and CEO of Camp4 Therapeutics Corp....
BioCentury | Jan 13, 2020
Company News

For $75M up front, Biogen will pursue Pfizer castoff for circadian rhythm in AD, PD

...submit a BLA for its flagship AD therapy aducanumab this year. The company partnered with Camp4 Therapeutics Corp....
BioCentury | Jan 11, 2020
Company News

Camp4’s platform to discover CNS targets in Biogen partnership

...Camp4 has entered a collaboration with Biogen to apply its platform to CNS target discovery. Camp4 Therapeutics Corp....
...clinical NASH candidate this year. Biogen declined to comment on the deal. Sandi Wong, Assistant Editor Biogen Inc. Camp4 Therapeutics Corp....
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

...as CFO. He was VP, head of commercial finance at Gilead Sciences Inc. (NASDAQ:GILD) . Camp4 Therapeutics Corp....
...of Cosmo Pharmaceuticals N.V. (SIX:COPN). Jonathan Block, Associate Editor Tempus Labs Inc. Vectura Group plc Editas Medicine Inc. Assembly Biosciences Inc. Camp4 Therapeutics Corp. Passage...
BioCentury | Sep 26, 2019
Company News

Omega: Flagship’s latest venture into the chromatin white space

...professors Rudolf Jaenisch and Richard Young. Young founded two other companies working on gene control: CAMP4 Therapeutics Corp....
BioCentury | Jan 25, 2019
Company News

Camp4, Alnylam partner to identify liver disease targets with machine learning

...Jan. 23. Camp4 Therapeutics Corp., Cambridge, Mass. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Business: Hepatic Sandi Wong Alnylam Pharmaceuticals Inc. Camp4 Therapeutics Corp. Gene...
BioCentury | Jan 23, 2019
Company News

Camp4, Alnylam partner to identify liver disease targets with machine learning

...royalties. Details were not disclosed. Alnylam was off $0.65 to $80.01 on Wednesday. Sandi Wong Alnylam Pharmaceuticals Inc. Camp4 Therapeutics Corp. Gene...
BioCentury | Jul 12, 2018
Emerging Company Profile

Gene control goals

...transcription factors that control the expression of every gene in a cell type of interest, Camp4 Therapeutics Corp....
...find targets that can regulate transcription for neurological diseases (see “Network Intelligence” ). COMPANY PROFILE Camp4 Therapeutics Corp....
...Horowitz, ShangPharm, additional undisclosed investors CEO: Josh Mandel-Brehm Patents: None issued Companies and Institutions Mentioned Camp4 Therapeutics Corp....
BioCentury | Jun 1, 2018
Financial News

CAMP4 Therapeutics launches with $30M series A

...spatial pattern of gene expression (see BioCentury Innovations, Oct. 26, 2017) . CAMP4 Therapeutics Corp., Cambridge, Mass. Sandi Wong Camp4 Therapeutics Corp....
BioCentury | May 31, 2018
Financial News

CAMP4 Therapeutics launches with $30M series A

...levels, timing and spatial pattern of gene expression (see BioCentury Innovations, Oct. 26, 2017) . Sandi Wong CAMP4 Therapeutics Corp....
Items per page:
1 - 10 of 10
BioCentury | Jul 29, 2020
Finance

With €27M at launch, Vico revives Prosensa oligonucleotide programs, aims to edit RNA for Rett

...Pureos, and the Droia fund. Mandel-Brehm is an entrepreneur partner at Polaris and CEO of Camp4 Therapeutics Corp....
BioCentury | Jan 13, 2020
Company News

For $75M up front, Biogen will pursue Pfizer castoff for circadian rhythm in AD, PD

...submit a BLA for its flagship AD therapy aducanumab this year. The company partnered with Camp4 Therapeutics Corp....
BioCentury | Jan 11, 2020
Company News

Camp4’s platform to discover CNS targets in Biogen partnership

...Camp4 has entered a collaboration with Biogen to apply its platform to CNS target discovery. Camp4 Therapeutics Corp....
...clinical NASH candidate this year. Biogen declined to comment on the deal. Sandi Wong, Assistant Editor Biogen Inc. Camp4 Therapeutics Corp....
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

...as CFO. He was VP, head of commercial finance at Gilead Sciences Inc. (NASDAQ:GILD) . Camp4 Therapeutics Corp....
...of Cosmo Pharmaceuticals N.V. (SIX:COPN). Jonathan Block, Associate Editor Tempus Labs Inc. Vectura Group plc Editas Medicine Inc. Assembly Biosciences Inc. Camp4 Therapeutics Corp. Passage...
BioCentury | Sep 26, 2019
Company News

Omega: Flagship’s latest venture into the chromatin white space

...professors Rudolf Jaenisch and Richard Young. Young founded two other companies working on gene control: CAMP4 Therapeutics Corp....
BioCentury | Jan 25, 2019
Company News

Camp4, Alnylam partner to identify liver disease targets with machine learning

...Jan. 23. Camp4 Therapeutics Corp., Cambridge, Mass. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Business: Hepatic Sandi Wong Alnylam Pharmaceuticals Inc. Camp4 Therapeutics Corp. Gene...
BioCentury | Jan 23, 2019
Company News

Camp4, Alnylam partner to identify liver disease targets with machine learning

...royalties. Details were not disclosed. Alnylam was off $0.65 to $80.01 on Wednesday. Sandi Wong Alnylam Pharmaceuticals Inc. Camp4 Therapeutics Corp. Gene...
BioCentury | Jul 12, 2018
Emerging Company Profile

Gene control goals

...transcription factors that control the expression of every gene in a cell type of interest, Camp4 Therapeutics Corp....
...find targets that can regulate transcription for neurological diseases (see “Network Intelligence” ). COMPANY PROFILE Camp4 Therapeutics Corp....
...Horowitz, ShangPharm, additional undisclosed investors CEO: Josh Mandel-Brehm Patents: None issued Companies and Institutions Mentioned Camp4 Therapeutics Corp....
BioCentury | Jun 1, 2018
Financial News

CAMP4 Therapeutics launches with $30M series A

...spatial pattern of gene expression (see BioCentury Innovations, Oct. 26, 2017) . CAMP4 Therapeutics Corp., Cambridge, Mass. Sandi Wong Camp4 Therapeutics Corp....
BioCentury | May 31, 2018
Financial News

CAMP4 Therapeutics launches with $30M series A

...levels, timing and spatial pattern of gene expression (see BioCentury Innovations, Oct. 26, 2017) . Sandi Wong CAMP4 Therapeutics Corp....
Items per page:
1 - 10 of 10